Lista de obras -

A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression

scientific article published on 05 December 2020

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

artículo científico publicado en 2008

A novel physical and functional association between nucleoside diphosphate kinase A and AMP-activated protein kinase alpha1 in liver and lung

scientific journal article

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

artículo científico publicado en 2008

Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product

artículo científico publicado en 2016

Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.

artículo científico publicado en 2014

Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management.

artículo científico

DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

artículo científico publicado en 2013

Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.

artículo científico

Expression of Intracellular Reactive Oxygen Species in Hematopoietic Stem Cells Correlates with Time to Neutrophil and Platelet Engraftment in Patients Undergoing Autologous Bone Marrow Transplantation

artículo científico publicado en 2018

Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples.

artículo científico publicado en 2016

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies

artículo científico publicado en 2023

Fludarabine Nucleoside Modulates Nuclear “Survival and Death” Proteins in Resistant Chronic Lymphocytic Leukemia Cells ⬇️

artículo científico publicado el 1 de diciembre de 2011

Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.

artículo científico publicado en 2012

Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells.

artículo científico publicado en 2013

Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.

artículo científico publicado en 2018

Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment

artículo científico publicado en 2017

Immune failure, infection and survival in chronic lymphocytic leukemia

artículo científico publicado en 2018

Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia.

artículo científico publicado en 2012

Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.

artículo científico publicado en 2017

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

scientific article published on 16 May 2018

Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells

artículo científico publicado en 2014

Molecular pathogenesis of chronic lymphocytic leukaemia

artículo científico publicado en 2019

Monoclonal B-lymphocytosis in patients aged over 90 years is common but not inevitable, and has a prevalence comparable to that in individuals aged 65-90 years.

artículo científico publicado en 2015

NDPK-A (but not NDPK-B) and AMPK alpha1 (but not AMPK alpha2) bind the cystic fibrosis transmembrane conductance regulator in epithelial cell membranes.

artículo científico publicado en 2006

Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?

scientific article published on 19 April 2013

Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site.

artículo científico publicado en 2007

Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors

artículo científico publicado en 2016

Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays

artículo científico publicado en 2017

Surface profiles for subclassification of chronic lymphocytic leukemia.

artículo científico

Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date

artículo científico publicado en 2015

The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia

artículo científico publicado en 2015

The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease ⬇️

artículo científico publicado el 31 de enero de 2012

The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine

artículo científico publicado en 2015

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment

artículo científico publicado en 2018

The future of laboratory testing in chronic lymphocytic leukaemia

scientific article published in 2021

The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway

artículo científico publicado en 2010

The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMP.

artículo científico publicado en 2009

Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

artículo científico publicado en 2016

ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis

scientific article published on 01 July 2006

ZAP-70 in B cell malignancies

artículo científico publicado en 2005

Lista de obras de

A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

A novel physical and functional association between nucleoside diphosphate kinase A and AMP-activated protein kinase alpha1 in liver and lung

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product

Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.

Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management.

DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.

Expression of Intracellular Reactive Oxygen Species in Hematopoietic Stem Cells Correlates with Time to Neutrophil and Platelet Engraftment in Patients Undergoing Autologous Bone Marrow Transplantation

Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples.

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies

Fludarabine Nucleoside Modulates Nuclear “Survival and Death” Proteins in Resistant Chronic Lymphocytic Leukemia Cells ⬇️

Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.

Hsp90 Inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells.

Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.

Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment

Immune failure, infection and survival in chronic lymphocytic leukemia

Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia.

Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells

Molecular pathogenesis of chronic lymphocytic leukaemia

Monoclonal B-lymphocytosis in patients aged over 90 years is common but not inevitable, and has a prevalence comparable to that in individuals aged 65-90 years.

NDPK-A (but not NDPK-B) and AMPK alpha1 (but not AMPK alpha2) bind the cystic fibrosis transmembrane conductance regulator in epithelial cell membranes.

Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?

Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site.

Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors

Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays

Surface profiles for subclassification of chronic lymphocytic leukemia.

Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date

The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia

The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease ⬇️

The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment

The future of laboratory testing in chronic lymphocytic leukaemia

The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway

The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMP.

Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis

ZAP-70 in B cell malignancies